183 related articles for article (PubMed ID: 28374823)
1. Inhibitory Effects of Dopamine Receptor D
Minami K; Liu S; Liu Y; Chen A; Wan Q; Na S; Li BY; Matsuura N; Koizumi M; Yin Y; Gan L; Xu A; Li J; Nakshatri H; Yokota H
Sci Rep; 2017 Apr; 7():45686. PubMed ID: 28374823
[TBL] [Abstract][Full Text] [Related]
2. Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells.
Liu S; Fan Y; Chen A; Jalali A; Minami K; Ogawa K; Nakshatri H; Li BY; Yokota H
Cancer Res; 2018 Jul; 78(14):3865-3876. PubMed ID: 29769195
[TBL] [Abstract][Full Text] [Related]
3. Preventing tumor progression to the bone by induced tumor-suppressing MSCs.
Sun X; Li K; Zha R; Liu S; Fan Y; Wu D; Hase M; Aryal UK; Lin CC; Li BY; Yokota H
Theranostics; 2021; 11(11):5143-5159. PubMed ID: 33859739
[No Abstract] [Full Text] [Related]
4. Dopamine D
Yang L; Yao Y; Yong L; Feng Y; Su H; Yao Q; Xue J; Lu W; Zhou T
Eur J Pharmacol; 2019 Sep; 859():172499. PubMed ID: 31242439
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting checkpoint kinase 1 protects bone from bone resorption by mammary tumor in a mouse model.
Liu S; Liu Y; Minami K; Chen A; Wan Q; Yin Y; Gan L; Xu A; Matsuura N; Koizumi M; Liu Y; Na S; Li J; Nakshatri H; Li BY; Yokota H
Oncotarget; 2018 Feb; 9(10):9364-9378. PubMed ID: 29507695
[TBL] [Abstract][Full Text] [Related]
6. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model.
Ko CH; Yue GG; Gao S; Luo KW; Siu WS; Shum WT; Shiu HT; Lee JK; Li G; Leung PC; Evdokiou A; Lau CB
J Ethnopharmacol; 2017 May; 204():77-85. PubMed ID: 28412218
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
11. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
12. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
13. Regulation of breast cancer-induced bone lesions by β-catenin protein signaling.
Chen Y; Shi HY; Stock SR; Stern PH; Zhang M
J Biol Chem; 2011 Dec; 286(49):42575-42584. PubMed ID: 22009747
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.
Hiraga T; Nakamura H
Int J Cancer; 2009 Jan; 124(1):215-22. PubMed ID: 18814279
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of D1 dopamine receptors exerts antidepressant-like activity in rats.
Desormeaux C; Demars F; Davenas E; Jay TM; Lavergne F
J Psychopharmacol; 2020 Dec; 34(12):1443-1448. PubMed ID: 33256509
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
19. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
20. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.
Fong JE; Le Nihouannen D; Komarova SV
J Biol Chem; 2010 Oct; 285(41):31427-34. PubMed ID: 20679341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
